Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurobiology and Treatment of Reading Disability in NF1
NCT02964884Phase 2Active, not recruiting
- Sponsor
- Vanderbilt University
- Start
- Nov 2016
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lovastatin in reading disability (RD) (4 arms), sponsored by Vanderbilt University. Primary endpoints: Woodcock Johnson Tests of Achievement IV at 24 weeks, Woodcock Reading Mastery Test-III at 24 weeks and 8 more. Started Nov 2016; status: active, not recruiting.
02
Drugs
lovastatin
03
Conditions
reading disability (RD)
Beyond the preview
Go deeper on NCT02964884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964884.